Scientific Publications

Trilaciclib

date publication
November 2021

Immune Profiling to Investigate Improved Survival in Patients with Metastatic Triple-Negative Breast Cancer Receiving Trilaciclib Prior to Chemotherapy

The Society for Immunotherapy of Cancer (SITC) (PDF)

October 2021

Real-World Burden of Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer Treated in the Community Oncology Setting 

Academy of Managed Care Pharmacy (AMCP) (PDF)

September 2021

PRESERVE 1: A Phase III, Randomized, Double-Blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer

European Society of Medical Oncology (ESMO) (PDF) or Smart Poster (mobile optimized)

August 2021

Trilaciclib Prior to Chemotherapy Reduces the Usage of Supportive Care Interventions for Chemotherapy-Induced Myelosuppression in Patients with Small Cell Lung Cancer: Pooled Analysis of Three Randomized Phase 2 Trials

Ferrarotto et al., Cancer Medicine

July 2021

Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: Pooled results from three phase 2, randomized, double-Blind, placebo-controlled studies

Hussein et al., Cancer Management and Research

July 2021

Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer

Gomez et al., International Journal of Cancer

June 2021

Effects of Trilaciclib Prior to Chemotherapy ± Atezolizumab on T-cell Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer (eAbstract)

American Society of Clinical Oncology (ASCO) (PDF) 

June 2021

PRESERVE 2: A Phase 3, Randomized, Double-Blind Trial of Trilaciclib versus Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

American Society of Clinical Oncology (ASCO) (PDF) or Smart Poster (mobile optimized)

May 2021

Cost-Benefit Analysis of Trilaciclib for the Prevention of Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (PDF) or Smart Poster (mobile optimized)

May 2021

Trends in Prevalence, Treatment Patterns, Myelosuppression, and Burden on the Health Care System Among Patients with Small Cell Lung Cancer: A SEER-Medicare Analysis 

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (PDF) or Smart Poster (mobile optimized)

April 2021

A Budget Impact Assessment of Trilaciclib for Decreasing the Incidence of Chemotherapy-Induced Myelosuppression in Adult Patients with Extensive-Stage Small Cell Lung Cancer

2021 Academy of Managed Care Pharmacy (ACMP) meeting: Poster (PDF) or Smart Poster (mobile optimized)

April 2021

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase 2 Randomized, Double-Blind, Placebo Controlled Studies

Weiss et al. Clinical Lung Cancer

Feb 2021

Cancer Patients' Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life.

Epstein et al., Patient Preference and Adherence

Feb 2021

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer

Li, C., Hart, L., Owonikoko, T.K. et al., Cancer Chemotherapy and Pharmacology

Dec 2020

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: a multicentre, randomised, double‐blind, placebo‐controlled phase II trial

Daniel et. al., International Journal of Cancer 

Dec 2020

Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized phase 2 trial

2020 San Antonio Breast Cancer Symposium (SABCS) Spotlight Poster Discussion: O’Shaugnessy et al., Poster #PD1-06 (PDF) or Smart Poster (mobile optimized)

Nov 2020

Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: Results from a randomized, double-blind, placebo-controlled Phase II study

Hart et al., Advances in Therapy

Oct 2020

Trilaciclib reduces the need for growth factors and red blood cell transfusions to manage chemotherapy-induced myelosuppression

North America Conference on Lung Cancer (NACLC) Oral Presentation: Ferrarotto et. al, Abstract# OA03.08 (PDF)

Oct 2020

Trilaciclib has myelopreservation benefits in patients with small cell lung cancer treated with chemotherapy, irrespective of age 

North America Conference on Lung Cancer (NACLC) Poster: Beck et. al., Poster# MO01.40 (PDF) or Smart Poster (mobile optimized)

Oct 2020

Using an exploratory composite endpoint to evaluate the myelopreservation benefits of trilaciclib in patients with small cell lung cancer

North America Conference on Lung Cancer (NACLC) Poster: Subramanian et. al., Poster# MO01.41 (PDF) or Smart Poster (mobile optimized)

Oct 2020

Myelopreservation with trilaciclib regardless of risk of chemotherapy-induced febrile neutropenia and/or anemia/red blood cell transfusions

North America Conference on Lung Cancer (NACLC) Poster: Hussein et al., Poster# MO01.42 (PDF) or Smart Poster (mobile optimized)

Oct 2020

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

Lai et al., Journal for ImmunoTherapy of Cancer

July 2020

Patient burden and real-world management of chemotherapy-induced myelosuppression: Results from an online survey of patients with solid tumors
Epstein et al., Advances in Therapy

May 2020

Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer
American Society of Clinical Oncology (ASCO) Virtual Meeting 2020 Poster: Weiss et al., Poster# 384 (PDF) or Smart Poster (mobile optimized)

May 2020 Impact of chemotherapy-induced myelosuppression on daily living: results of a U.S. online survey of patients with cancer
ISPOR 2020 Congress Poster: Epstein et al., Poster# PCN333 (PDF) or Smart Poster (mobile optimized)
Sep 2019 Trilaciclib decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
ESMO 2019 Congress Poster: Daniel et al., Abstract #1742PD (pdf) or SmartPoster (mobile optimized) 
Sep 2019 Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
Tan et al., Lancet Oncology 
Sep 2019 Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GCb) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized, open-label, Phase 2 trial
ESMO 2019 Congress Presentation: O’Shaugnessy et al., Oral Presentation (pdf) 
Aug 2019 Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial
Weiss et al., Annals of Oncology 
Jun 2019 Positive effects of trilaciclib on patient myelosuppression-related symptoms and functioning: results from three phase 2 randomized, double-blind, placebo-controlled small cell lung cancer trials
MASCC Oral Presentation: Weiss et al., Abstract #MASCC9-0845 (pdf)
Jun 2019 Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer
ASCO Oral Presentation: Hart et al., Abstract #8505 (pdf)
Dec 2018 Trilaciclib, a CDK4/6 inhibitor, dosed with Gemcitabine, Carboplatin in metastatic triple negative breast cancer (mTNBC) patients: Preliminary Phase 2 results
SABCS Poster: O'Shaughnessy et al., Abstract #1191 (pdf)
Nov 2018 Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models
EORTC-NCI-AACR Symposium Poster: Sorrentino et al., Abstract #377 (pdf)
Oct 2018 Trilaciclib decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving 1st line chemotherapy
ESMO 2018 Congress Poster: Dragnev et al., Abstract #1666PD (pdf)
Oct 2018 Trilaciclib preserves and enhances immune system function in extensive-stage small cell lung cancer (SCLC) patients receiving first-line chemotherapy
ESMO 2018 Congress Poster: Sorrentino et al., Abstract #1671P (pdf)
Apr 2018 Transient exposure to trilaciclib, a CDK4/6 inhibitor, modulates gene expression in tumor immune infiltrates and promotes a pro-inflammatory tumor microenvironment
AACR Annual Meeting Poster: Lai et al., Abstract #1752 (pdf)
Nov 2017 CDK4/6 inhibition augments anti-tumor immunity by enhancing T cell activation
Deng et al., Cancer Discovery
Jun 2017 Trilaciclib (G1T28): a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC): Phase 1b results
ASCO Annual Meeting Poster: Rocha Lima et al., Abstract #8568 (pdf)
Apr 2017 Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
He et al., Science Translational Medicine
Apr 2017 Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models
AACR Annual Meeting Poster: Sorrentino et al., Abstract #5628 (pdf)
Dec 2016 Trilaciclib (G1T28), a cyclin dependent kinase 4/6 inhibitor, in combination with topotecan for previously treated small cell lung cancer: preliminary results
WCLC Annual Meeting Poster: Hart et al., Abstract #5213 (pdf)
Nov 2016 Trilaciclib (G1T28), a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy
EORTC-NCI-AACR Symposium Poster: Roberts et al., Abstract #439 (pdf)
May 2016 Preclinical characterization of G1T28: a novel CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression
Bisi et al., Molecular Cancer Therapeutics (pdf)
Apr 2016 G1T28, a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin for extensive stage small cell lung cancer (ES-SCLC): preliminary results
AACR Annual Meeting Poster: Rocha Lima et al., Abstract #CT151 (pdf)
May 2015 Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression
ASCO Annual Meeting Poster: Roberts et al., Abstract #2529 (pdf)
May 2015 First-in-human phase 1a safety, PK, and PD study of the CDK4/6 inhibitor G1T28 (G1T28-1-01)
ASCO Annual Meeting Poster: Tiessen et al., Abstract #2527 (pdf)
Apr 2015 Pre-clinical characterization of G1T28, a novel CDK4/6 inhibitor for protection of bone marrow from cytotoxic chemotherapies
AACR Annual Meeting Poster: Bisi et al., Abstract #1784 (pdf)

Rintodestrant

Date Publication
June 2021

Rintodestrant (G1TG48), an Oral Selective Estrogen Receptor Degrader, in Combination with Palbociclib for ER+/HER2- Advanced Breast Cancer: Phase 1 Results

American Society of Clinical Oncology (ASCO) (PDF) or Smart Poster (mobile optimized)

Dec 2020

Pharmacodynamic analysis from a Phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2-locally advanced or metastatic breast cancer

2020 San Antonio Breast Cancer Symposium (SABCS) Poster: Aftimos et al., Poster #PD8-07 (PDF) or Smart Poster (mobile optimized)

Dec 2020

Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2-locally advanced or metastatic breast cancer: Updated Phase 1 results and dose selection

2020 San Antonio Breast Cancer Symposium (SABCS) Poster: Aftimos et al., Poster #PS12-04 (PDF) or Smart Poster (mobile optimized)

Dec 2020

Population pharmacokinetic and exposure-response modeling of theoral selective estrogen receptor degrader rintodestrant (G1T48) in patients with ER+/HER2-advanced breast cancer

2020 San Antonio Breast Cancer Symposium (SABCS) Poster: Li et al., Poster #PS17-08 (PDF) or Smart Poster (mobile optimized)

Mar 2020

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine‑resistant breast cancer

Andreano et al., Breast Cancer Research and Treatment (pdf)

Sep 2019

First-in-human dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)
ESMO 2019 Congress Poster: Dees et al., Abstract #340P (pdf) or SmartPoster (mobile optimized)

Apr 2017

Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in an animal model of tamoxifen resistant breast cancer
AACR Annual Meeting Poster: Wardell et al., Abstract #5641 (pdf)